Core Viewpoint - The TransMedics Group, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934, with claims of misconduct including fraudulent practices and safety issues [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Jewik v. TransMedics Group, Inc., and covers purchasers of TransMedics securities from February 28, 2023, to January 10, 2025 [1]. - Investors have until April 15, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate business [3]. Group 2: Allegations Against TransMedics - Allegations include unsafe practices and a lack of safety oversight, which heightened regulatory scrutiny risks [3]. - A letter from U.S. Representative Paul Gosar on February 21, 2024, accused TransMedics of misconduct, leading to a decline in stock price [4]. - A report from Scorpion Capital on January 10, 2025, accused TransMedics of overbilling and providing rejected organs to patients, further impacting stock price negatively [5]. Group 3: Legal Process and Representation - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased TransMedics securities during the class period to seek lead plaintiff status [6]. - The lead plaintiff represents the interests of all class members and can choose a law firm for litigation [6]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud cases, having recovered $6.6 billion for investors in class action cases [7]. - The firm has been ranked 1 in securing monetary relief for investors for six out of the last ten years [7].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of TransMedics Group, Inc. regarding a class action lawsuit alleging fraudulent practices and safety issues during the specified class period [1][2]. Group 1: Allegations Against TransMedics - The complaint alleges that TransMedics engaged in kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue [1]. - It is claimed that TransMedics engaged in unsafe practices, concealed safety issues, and lacked adequate safety oversight [1]. - The aforementioned practices have subjected TransMedics to increased scrutiny and regulatory risk, leading to materially false and misleading statements about its business and operations [1]. Group 2: Class Action Details - The class period for the lawsuit is from February 28, 2023, to January 10, 2025, and shareholders are encouraged to register for participation [1][2]. - The deadline for shareholders to seek lead plaintiff status is April 15, 2025, and there is no cost or obligation to participate in the case [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2]. Group 3: About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Group 1 - The importance of reliable and advancing medical equipment is increasing, particularly in the field of organ transplantation due to the growing issue of end-stage organ failure worldwide [1]

Core Viewpoint - A class action lawsuit has been filed against TransMedics Group, Inc. for violations of federal securities laws, impacting investors who purchased shares during the specified Class Period [1][2]. Group 1: Lawsuit Details - The lawsuit alleges that TransMedics and its officers made false or misleading statements and failed to disclose critical information regarding the company's business practices [2]. - Specific allegations include the use of kickbacks, fraudulent overbilling, and coercive tactics to generate revenue, as well as unsafe practices and lack of safety oversight [2]. Group 2: Impact on Investors - Following the revelation of these issues, TransMedics' stock experienced a significant decline, resulting in financial losses for investors [3]. - Investors who suffered losses exceeding $100,000 are encouraged to participate in the lawsuit, with a deadline to act by April 15, 2025 [3]. Group 3: About the Law Firm - Lowey Dannenberg P.C. specializes in representing investors who have suffered financial losses due to corporate fraud and has a history of recovering billions for clients [4].

Core Viewpoint - A class-action lawsuit has been filed against TransMedics Group, Inc. alleging fraudulent practices and safety issues, impacting investors who acquired securities between February 28, 2023, and January 10, 2025 [1][2]. Group 1: Allegations and Claims - The lawsuit claims that TransMedics made false and misleading statements, failed to disclose crucial information, and engaged in kickbacks, fraudulent overbilling, and coercive tactics to enhance business and revenue [2][5]. - It is alleged that the company concealed safety problems and lacked adequate safety oversight, which exposed it to increased regulatory risk [2][5]. Group 2: Events Impacting Stock Price - On February 21, 2024, Representative Paul Gosar accused TransMedics of misappropriating corporate resources, leading to a stock price drop following media coverage [3]. - A report released by activist short seller Scorpion Capital on January 10, 2025, accused TransMedics of overbilling hospitals and coercing customers, further depressing the company's stock price [4]. Group 3: Investigation and Legal Proceedings - Hagens Berman is investigating the claims against TransMedics and is urging investors who suffered losses to come forward [2][5]. - The lead plaintiff deadline for the class-action lawsuit is set for April 15, 2025 [2].

Core Viewpoint - A class action securities lawsuit has been filed against TransMedics Group, Inc. for alleged securities fraud affecting investors between February 28, 2023, and January 10, 2025 [1][2]. Group 1: Allegations Against TransMedics - The lawsuit claims that TransMedics engaged in kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue [2]. - It is alleged that the company engaged in unsafe practices, concealed safety issues, and lacked proper safety oversight [2]. - The aforementioned actions reportedly increased the company's risk of scrutiny and regulatory challenges, leading to materially false and misleading statements about its business and operations [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until April 15, 2025, to request to be appointed as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and participation does not require serving as a lead plaintiff [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A securities class action lawsuit has been filed against TransMedics Group, Inc. for alleged misconduct during the Class Period from February 28, 2023, to January 10, 2025 [1] Allegations Against TransMedics - The complaint alleges that TransMedics engaged in kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue [3] - It is claimed that the company engaged in unsafe practices, concealed safety issues, and lacked proper safety oversight [3] - These actions purportedly exposed TransMedics to increased scrutiny and regulatory risks [3] Lead Plaintiff Process - Investors in TransMedics have until April 15, 2025, to seek appointment as a lead plaintiff representative for the class [4] - A lead plaintiff acts on behalf of all class members and is typically the investor or group of investors with the largest financial interest [4] - The decision to serve as a lead plaintiff does not affect the ability to share in any recovery [4]

Core Viewpoint - A class action lawsuit has been filed against TransMedics Group, Inc. for alleged violations of federal securities laws, with claims of misleading statements and unsafe practices [1][2][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased TransMedics securities between February 3, 2022, and February 3, 2025 [2]. - Allegations include the use of kickbacks, fraudulent overbilling, and coercive tactics to generate revenue, as well as a lack of safety oversight [3]. Group 2: Next Steps for Investors - Investors who suffered losses in TransMedics have until April 15, 2025, to request appointment as lead plaintiff in the case [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - The law firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5]. - Bronstein, Gewirtz & Grossman, LLC has a history of recovering hundreds of millions of dollars for investors in securities fraud cases [6].

Core Viewpoint - A securities class action lawsuit has been filed against TransMedics Group, Inc. for alleged misconduct during the class period from February 28, 2023, to January 10, 2025, with a lead plaintiff deadline set for April 15, 2025 [1]. Allegations Against TransMedics - The complaint alleges that TransMedics engaged in unethical practices, including the use of kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue [2]. - It is claimed that TransMedics engaged in unsafe practices, concealed safety issues, and lacked proper safety oversight, which increased the risk of regulatory scrutiny [2]. Lead Plaintiff Process - Investors in TransMedics have until April 15, 2025, to seek appointment as a lead plaintiff representative or may choose to remain absent from the class [3]. - The lead plaintiff will represent the interests of all class members and select counsel to direct the litigation [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].

SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons or entities who purchased or otherwise acquired TransMedics Group, Inc. (NASDAQ: TMDX) securities between February 28, 2023 and January 10, 2025. TransMedics describes itself as a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. For more information, submit a form, email attor ...